Renaissance Technologies (RenTech)'s ALLO Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC (Rentech)) currently holds 2.19 M shares of Allogene Therapeutics, Inc. (ALLO) worth $3 M, representing 0.00% of the portfolio. First purchased in 2020-Q2, this medium-term investment has been held for 20 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in ALLO, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2024, adding 1.35 M shares. Largest reduction occurred in Q3 2024, reducing 1.11 M shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Allogene Therapeutics (ALLO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Allogene Therapeutics (ALLO) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -706,728 | Reduce 24.42% | 2.19 M | $1.37 |
| Q3 2025 | +1.22 M | Add 73.28% | 2.89 M | $1.24 |
| Q2 2025 | +113,312 | Add 7.28% | 1.67 M | $1.13 |
| Q1 2025 | +1 M | Add 180.72% | 1.56 M | $1.46 |
| Q4 2024 | -87,468 | Reduce 13.62% | 554,541 | $2.13 |
| Q3 2024 | -1.11 M | Reduce 63.27% | 642,009 | $2.80 |
| Q2 2024 | +1.35 M | Add 340.40% | 1.75 M | $2.33 |
| Q1 2024 | -61,748 | Reduce 13.46% | 396,900 | $4.47 |
| Q4 2023 | +428,366 | Add 1414.59% | 458,648 | $3.21 |
| Q3 2023 | -221,618 | Reduce 87.98% | 30,282 | $3.17 |
| Q2 2023 | -176,800 | Reduce 41.24% | 251,900 | $0.00 |
| Q1 2023 | -11,400 | Reduce 2.59% | 428,700 | $0.00 |
| Q4 2022 | +440,100 | New Buy | 440,100 | $0.01 |
| Q2 2022 | -974,700 | Sold Out | 0 | $0.00 |
| Q1 2022 | +974,700 | New Buy | 974,700 | $9.11 |
| Q3 2021 | -704,400 | Sold Out | 0 | $0.00 |
| Q2 2021 | +704,400 | New Buy | 704,400 | $26.08 |
| Q4 2020 | -83,900 | Sold Out | 0 | $0.00 |
| Q3 2020 | +58,700 | Add 232.94% | 83,900 | $37.71 |
| Q2 2020 | +25,200 | New Buy | 25,200 | $42.82 |
Renaissance Technologies (RenTech)'s Allogene Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Allogene Therapeutics, Inc. (ALLO) in Q2 2020, acquiring 25,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Allogene Therapeutics, Inc. (ALLO) for 20 quarters since Q2 2020.
Renaissance Technologies (RenTech)'s largest addition to Allogene Therapeutics, Inc. (ALLO) was in Q2 2024, adding 1,747,955 shares worth $4.07 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC (Rentech), owns 2,187,084 shares of Allogene Therapeutics, Inc. (ALLO), valued at approximately $3 M.
As of the Q4 2025 filing, Allogene Therapeutics, Inc. (ALLO) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Allogene Therapeutics, Inc. (ALLO) was 2,893,812 shares, as reported at the end of Q3 2025.